| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
PSB-0788 targets the adenosine A2B receptor, a G protein-coupled receptor that is activated by the endogenous nucleoside adenosine. The A2B receptor is involved in various physiological and pathological processes, including inflammation, fibrosis, and vasodilation. PSB-0788 is a potent and selective antagonist of the A2B receptor. It exhibits an IC50 of 3.64 nM and a Ki of 0.393 nM at human A2B receptors. It displays >100-fold selectivity over the A1, A2A, and A3 adenosine receptor subtypes, making it a valuable tool for studying the specific role of the A2B receptor.
|
|---|---|
| ln Vitro |
PSB-0788 (compound 17) exhibits a high potency of 3.64 nM (IC50) on A2BAdoR. With Ki values of 0.393 nM for A2B human recombinant, >1000 nM for A3 human recombinant, 333 nM for A2A human recombinant, 1730 nM for A2A rat brain striatal body membrane, 2240 nM for A1 human recombinant, and 386 nM for A1 rat cortical membrane, PSB-0788 exhibits good affinity and selectivity [1].
In vitro, PSB-0788 exhibits high potency and selectivity for the A2B receptor. It has an IC50 of 3.64 nM and a Ki of 0.393 nM at the human A2B receptor. It displays >100-fold selectivity over other adenosine receptor subtypes: Ki values for A3 human recombinant >1000 nM, A2A human recombinant 333 nM, and A1 human recombinant 2240 nM. This high selectivity makes PSB-0788 an ideal tool for studying A2B receptor-mediated signaling and its role in various diseases, particularly chronic inflammatory lung disease. |
| ln Vivo |
In vivo, PSB-0788 is indicated for the study of chronic inflammatory lung disease. As a selective A2B receptor antagonist, it can be used in animal models to investigate the role of the A2B receptor in pulmonary inflammation, fibrosis, and other respiratory conditions. However, specific in vivo protocols and results, such as dosing regimens, routes of administration, and efficacy in disease models, are not detailed in the available literature. The compound's high potency and selectivity make it a promising tool for in vivo studies.
|
| Enzyme Assay |
The in vitro assays for PSB-0788 measure its binding affinity and antagonistic activity at the adenosine A2B receptor. Receptor binding assays are performed using membranes from cells expressing the human A2B receptor and a radiolabeled A2B receptor ligand. PSB-0788 is added at increasing concentrations to compete with the labeled ligand. The Ki is determined from the competition curve. Functional assays measure the compound's ability to inhibit A2B receptor-mediated signaling, such as cAMP accumulation. Cells expressing the A2B receptor are treated with an A2B receptor agonist (e.g., NECA) in the presence of PSB-0788, and the inhibition of cAMP production is measured.
|
| Cell Assay |
In vitro cell-based assays for PSB-0788 are conducted using cells expressing the human A2B receptor. In a typical assay, cells are seeded in multi-well plates and treated with an A2B receptor agonist (e.g., NECA) to stimulate cAMP production. PSB-0788 is added at various concentrations, and the levels of cAMP are measured using a competitive immunoassay. The IC50, which is the concentration that inhibits 50% of the agonist-induced cAMP production, is determined from the dose-response curve. For PSB-0788, the IC50 is 3.64 nM. These assays confirm the compound's potent antagonistic activity at the A2B receptor.
|
| Animal Protocol |
In vivo animal experiments for PSB-0788 are conducted in models of chronic inflammatory lung disease, such as allergen-induced airway inflammation or bleomycin-induced pulmonary fibrosis. In a typical study, PSB-0788 is administered orally or by injection to the animals. Inflammatory parameters, such as cell infiltration, cytokine levels, and tissue damage, are assessed. The compound's ability to reduce inflammation and improve lung function is measured. However, specific protocols for PSB-0788 are not detailed in the available literature. Its use is limited to research applications.
|
| ADME/Pharmacokinetics |
PSB-0788 has a molecular weight of 543.04 g/mol and a molecular formula of C25H27ClN6O4S. It has a logP of 3.606. It is a solid at room temperature. For storage, it is recommended to keep the powder at -20°C for up to 3 years or at 4°C for up to 2 years. In solvent, it can be stored at -80°C for 6 months or at -20°C for 1 month. Detailed pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) have not been extensively characterized. The compound is a research tool and is not intended for human use.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for PSB-0788 is not provided in standard product descriptions. As a research compound, its toxicity profile has not been extensively characterized. The compound is a potent and selective A2B receptor antagonist, and its toxicity would be related to its effects on A2B receptor-mediated signaling in normal tissues. However, comprehensive toxicological studies have not been reported. As with all research chemicals, standard laboratory safety precautions should be followed when handling PSB-0788. Its use is limited to research applications and it is not intended for human or veterinary use.
|
| References |
[1]. Thomas Borrmann, et al. 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J Med Chem. 2009 Jul 9;52(13):3994-4
|
| Additional Infomation |
PSB-0788 is a research compound and is not approved for any clinical or therapeutic use. It is a potent and selective antagonist of the adenosine A2B receptor, with an IC50 of 3.64 nM and a Ki of 0.393 nM. It displays >100-fold selectivity over the A1, A2A, and A3 adenosine receptor subtypes. PSB-0788 is used as a research tool to study the role of the A2B receptor in various physiological and pathological processes, particularly in chronic inflammatory lung disease. Its mechanism of action involves blocking the A2B receptor, thereby inhibiting adenosine-mediated signaling. It is a valuable tool for validating the A2B receptor as a therapeutic target.
|
| Molecular Formula |
C25H27CLN6O4S
|
|---|---|
| Molecular Weight |
543.04
|
| Exact Mass |
542.15
|
| CAS # |
1027513-54-7
|
| PubChem CID |
44186581
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.606
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
924
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCN1C(=O)NC2N=C(C3=CC=C(S(N4CCN(CC5=CC=C(Cl)C=C5)CC4)(=O)=O)C=C3)NC=2C1=O
|
| InChi Key |
JQZJACVYMPKVDS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H27ClN6O4S/c1-2-11-32-24(33)21-23(29-25(32)34)28-22(27-21)18-5-9-20(10-6-18)37(35,36)31-14-12-30(13-15-31)16-17-3-7-19(26)8-4-17/h3-10H,2,11-16H2,1H3,(H,27,28)(H,29,34)
|
| Chemical Name |
8-[4-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]sulfonylphenyl]-1-propyl-3,7-dihydropurine-2,6-dione
|
| Synonyms |
PSB-0788 PSB0788 PSB 0788
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8415 mL | 9.2074 mL | 18.4148 mL | |
| 5 mM | 0.3683 mL | 1.8415 mL | 3.6830 mL | |
| 10 mM | 0.1841 mL | 0.9207 mL | 1.8415 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
